Clinical Trials Browser

Carcinoma, Transitional Cell

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Nasopharyngeal Carcinoma

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

HR+HER2- Breast Cancer

Uterine Cervical Neoplasms

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

Biliary Tract Neoplasms

Ovarian Neoplasms

Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Carcinoma, Transitional Cell

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Nasopharyngeal Neoplasms

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Lymphoma, Large B-Cell, Diffuse

Pancreatic Neoplasms

Urinary Bladder Neoplasms

Lymphoma, Large B-Cell, Diffuse

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Lung Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Triple Negative Breast Neoplasms

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

Uterine Cervical Neoplasms

Pancreatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Pancreatic Neoplasms

Lymphoma, Large B-Cell, Diffuse

Breast Neoplasms, Neoplasm Metastasis

Urinary Bladder Neoplasms

Pancreatic Neoplasms

Biliary Tract Neoplasms

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Ovarian Neoplasms

Nasopharyngeal Carcinoma

Clinical Trials

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

TroFuse-019

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

TroFuse-020

FRAmework-01

DESTINY-BTC01

MAESTRA 2

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

KEYNOTE-966

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

INTerpath-009

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

SunRISe-2

SunRISe-5

MoonRISe-1

TroFuse-011

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

OLYMPIA-4

EPCORE DLBCL-4

LAP100

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

GAIN-BCG

ASCENT-03

TERZO

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

RASolute 303

BRIDGE

PRISM-1

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

TOURMALINE

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

KEYNOTE-966

LOTIS 5

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC